Cresset Asset Management LLC Reduces Position in DexCom, Inc. (NASDAQ:DXCM)

Cresset Asset Management LLC lowered its holdings in DexCom, Inc. (NASDAQ:DXCM) by 52.1% in the fourth quarter, HoldingsChannel reports. The firm owned 21,454 shares of the medical device company’s stock after selling 23,375 shares during the period. Cresset Asset Management LLC’s holdings in DexCom were worth $1,668,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Private Trust Co. NA boosted its stake in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after buying an additional 245 shares during the last quarter. Optiver Holding B.V. bought a new position in DexCom during the 4th quarter valued at $33,000. TD Private Client Wealth LLC grew its holdings in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after acquiring an additional 167 shares in the last quarter. Larson Financial Group LLC increased its position in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after purchasing an additional 137 shares during the last quarter. Finally, Heck Capital Advisors LLC acquired a new stake in shares of DexCom in the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on DXCM shares. Barclays boosted their price objective on DexCom from $90.00 to $93.00 and gave the company an “equal weight” rating in a report on Monday, May 5th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Canaccord Genuity Group increased their target price on shares of DexCom from $103.00 to $106.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. Finally, Morgan Stanley lifted their price target on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $98.11.

DexCom Price Performance

Shares of DXCM opened at $84.66 on Friday. DexCom, Inc. has a one year low of $57.52 and a one year high of $132.26. The stock’s fifty day moving average is $71.08 and its 200-day moving average is $77.20. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market capitalization of $33.20 billion, a price-to-earnings ratio of 59.20, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. DexCom’s revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.32 EPS. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Transactions at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 32,498 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now directly owns 372,029 shares in the company, valued at approximately $26,183,401.02. The trade was a 8.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the transaction, the executive vice president now owns 105,602 shares of the company’s stock, valued at approximately $7,432,268.76. This trade represents a 10.96 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 66,926 shares of company stock valued at $4,734,384. Corporate insiders own 0.32% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.